MedTrace Logo

Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia

NCT03809702 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2020-10-14

No results posted yet for this study

Summary

All eligible Herpes Zoster patients will be randomized into two groups. Group 1 will be the treatment group receiving Pregabalin 75 mg twice daily for 4 weeks in addition to other routine treatment. Whereas, group 2 will be the control group receiving all routine treatment similar to group 1 except Pregabalin. Instead control group will receive Placebo.

Conditions

  • Herpes Zoster

Interventions

DRUG

Pregabalin

Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)

DRUG

Placebo

Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)

Sponsors & Collaborators

  • University Grants Commission

    collaborator OTHER

  • B.P. Koirala Institute of Health Sciences

    lead OTHER

Principal Investigators

  • Suchana Marahatta, MBBS, MD · B.P. Koirala Institute of Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-15
Primary Completion
2019-09-20
Completion
2019-12-30

Countries

  • Nepal

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03809702 on ClinicalTrials.gov